Cathinone neurotoxicity (“The “3Ms”)

Current Neuropharmacology

Volumn 13, Issue 1, 2015, Pages 21-25

  Karch, Steven B ^a  

^a NONE   (United States)

Author keywords

Cathinones; MDMA; MDVP; Methedrone; Methelone; Bath salts

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; BENZODIAZEPINE; CANNABIS; CATHINONE; COCAINE; DESIGNER DRUG; DOPAMINE TRANSPORTER; METHAMPHETAMINE; METHYLENEDIOXYPYROVALERONE; METHYLONE; NORADRENALIN TRANSPORTER; OXAZEPAM; PSYCHOTROPIC AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; ALKALOID;

ARTICLE; AUTOPSY; BRAIN EDEMA; CONGESTIVE CARDIOMYOPATHY; DELIRIUM; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG SYNTHESIS; ELECTROCARDIOGRAPHY; EXCITED DELIRIUM SYNDROME; HOSPITALIZATION; HUMAN; MORTALITY; NEURONAL CHANNELOPATHY; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOSIS; SEIZURE; SUDDEN DEATH; UNITED NATIONS; CHEMICALLY INDUCED; PSYCHOLOGY; TOXICITY AND INTOXICATION;

ALKALOIDS; DELIRIUM; DESIGNER DRUGS; HUMANS; NEUROTOXICITY SYNDROMES;

EID: 84929335284     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666141210225009     Document Type: Article

References (43)

1. U.S. National Defense Intellegence Center. Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat. Situation Report, 2011.
2. U.S. Defense Intellegency Agency In Media Round Table on Synthetic Drugs, 2011.
3. (EMCDDA), European Center for Drugs and Drug Addiction. The state of the drugs problem in Europe; European Union: Luxemberg, 2010.
4. Wood, D. M.; Greene, S. L.; Dargan, P. I. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. EMJ, 2011, 28 (4), 280-2. doi:10.1136/emj.2010.092288
5. Baumann, M. H.; Ayestas, M. A., Jr.; Partilla, J. S.; Sink, J. R.; Shulgin, A. T.; Daley, P. F.; Brandt, S. D.; Rothman, R. B.; Ruoho, A. E.; Cozzi, N. V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology, 2012, 37 (5), 1192-203. doi:10.1038/npp.2011.304
6. Brandt, S.; Sunnall, H.; Measham, F.; Cole, J. Analyses of secondgeneration 'legal highs' in the UK: initial findings. Drug Test Anal., 2010, 2 (8), 377-382. DOI: 10.1002/dta.155
7. Schifano, F.; Albanese, A.; Fergus, S.; Stair, J. L.; Deluca, P.; Corazza, O.; Davey, Z.; Corkery, J.; Siemann, H.; Scherbaum, N.; Farre, M.; Torrens, M.; Demetrovics, Z.; Ghodse, A. H.; Psychonaut Web, M.; Re, D. R. G. Mephedrone (4- methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology, 2011, 214 (3), 593-602. DOI10.1007/s00213-010-2070-x
8. Wood, D. M.; Davies, S.; Greene, S. L.; Button, J.; Holt, D. W.; Ramsey, J.; Dargan, P. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin. Toxicol. (Phila) 2010, 48 (9), 924-7. doi:10.3109/15563650.2010.531021
9. Regan, L.; Mitchelson, M.; Macdonald, C. Mephedrone toxicity in a Scottish emergency department. EMJ, 2011, 28 (12), 1055-8. doi:10.1136/emj.2010.103093
10. James, D.; Adams, R. D.; Spears, R.; Cooper, G.; Lupton, D. J.; Thompson, J. P.; Thomas, S. H. National Poisons Information, S. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. EMJ, 2011, 28 (8), 686-9. doi:10.1136/emj.2010.096636
11. Wood, D. M.; Greene, S. L.; Dargan, P. I. Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. EMJ, 2013, 30 (1), 70-1. doi:10.1136/emermed-2011-200747
12. Aromatario, M.; Bottoni, E.; Santoni, M.; Ciallella, C. New "Lethal highs": A case of a deadly cocktail of GHB and Mephedrone. Forensic Sci.Intl., 2012, 223 (1-3), e38-41
13. Adamowicz, P.; Tokarczyk, B.; Stanaszek, R.; Slopianka, M., Fatal mephedrone intoxication--a case report. J. Anal. Toxicol., 2013, 37 (1), 37-42. .doi: 10.1093/jat/bks085
14. Lusthof, K. J.; Oosting, R.; Maes, A.; Verschraagen, M.; Dijkhuizen, A.; Sprong, A. G. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci. Intl., 2011, 206 (1-3), e93-5. doi:10.1016/j.forsciint.2010.12.014
15. Gerace, E.; Petrarulo, M.; Bison, F.; Salomone, A.; Vincenti, M. Toxicological findings in a fatal multidrug intoxication involving mephedrone. Forensic Sci. Int., 2014, 243C, 68-73. doi:10.1016/ j.forsciint.2014.04.038
16. Bossong, M. G.; Van Dijk, J. P.; Niesink, R. J. Methylone and mCPP, two new drugs of abuse? Addict. Biol., 2005, 10 (4), 321-3. DOI: 10.1080/13556210500350794
17. Baumann, M.H.; Ayestas, M.A. Jr.; Partilla, J.S.; Sink, J.R.; Shulgin, A.T.; Daley P.F.; Brandt, S.D.; Rothman, R.B.; Ruoho, A.E.; Cozzi, N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology, 2013, 37 (5), 1192-11203. doi:10.1038/npp.2011.304
18. Meyer, M. R.; Wilhelm, J.; Peters, F. T.; Maurer, H. H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem., 2010, 397 (3), 1225-33. DOI 10.1007/s00216-010-3636-5
19. Pedersen, A. J.; Petersen, T. H.; Linnet, K. In vitro metabolism and pharmacokinetic studies on methylone. Drug Metab. Dispos., 2013, 41 (6), 1247-55. doi: 10.1124/dmd.112.050880
20. Kamata, H. T.; Shima, N.; Zaitsu, K.; Kamata, T.; Miki, A.; Nishikawa, M.; Katagi, M.; Tsuchihashi, H. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica, 2006, 36 (8), 709-23. doi: 10.1080/ 00498250600780191
21. Murray, B. L.; Murphy, C. M.; Beuhler, M. C. Death Following Recreational Use of Designer Drug "Bath Salts" Containing 3, 4- Methylenedioxypyrovalerone (MDPV). J. Med. Toxicol., 2012, 8 (1), 69-75. DOI10.1007/s13181-011-0196-9
22. Cawrse, B. M.; Levine, B.; Jufer, R. A.; Fowler, D. R.; Vorce, S. P.; Dickson, A. J.; Holler, J. M. Distribution of methylone in four postmortem cases. J. Anal. Toxicol., 2012, 36 (6), 434-9. doi: 10.1093/jat/bks046
23. Karch, S. Changing times: DNA resequencing and the "nearly normal heart". J. Forensic Leg. Med., 2007, 14(7), 389-97. doi:10.1016/j.jflm.2007.04.008
24. Carbone, P. N.; Carbone, D. L.; Carstairs, S. D.; Luzi, S. A. Sudden cardiac death associated with methylone use. Am. J. Forensic Med. Pathol., 2013, 34 (1), 26-8. doi: 10.1097/PAF.0b013e31827ab5da.
25. Pearson, J. M.; Hargraves, T. L.; Hair, L. S.; Massucci, C. J.; Frazee, C. C., 3rd; Garg, U.; Pietak, B. R. Three fatal intoxications due to methylone. J. Anal. Toxicol., 2012, 36 (6), 444-51. doi: 10.1093/jat/bks043
26. Warrick, B. J.; Wilson, J.; Hedge, M.; Freeman, S.; Leonard, K.; Aaron, C. Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol., 2012, 8 (1), 65-8. DOI10.1007/s13181- 011-0199-6
27. Lopez-Arnau, R.; Martinez-Clemente, J.; Carbo, M.; Pubill, D.; Escubedo, E.; Camarasa, J. An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts". Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 45, 64-72. doi:10.1016/j.pnpbp. 2013.04.007
28. Watterson, L. R.; Hood, L.; Sewalia, K.; Tomek, S. E.; Yahn, S.; Johnson, C. T.; Wegner, S.; Blough, B. E.; Marusich, J. A.; Olive, M. F. The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts". J. Addict. Res. Ther., 2012, Suppl 9.
29. Marusich, J. A.; Antonazzo, K. R.; Wiley, J. L.; Blough, B. E.; Partilla, J. S.; Baumann, M. H. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3, 4- methylenedioxypyrovalerone (MDPV). Neuropharmacology, 2014. doi:10.1016/j.neuropharm.2014.02.016
30. Nagai, H.; Saka, K.; Nakajima, M.; Maeda, H.; Kuroda, R.; Igarashi, A.; Tsujimura-Ito, T.; Nara, A.; Komori, M.; Yoshida, K., Sudden death after sustained restraint following self-administration of the designer drug alpha-pyrrolidinovalerophenone. Intl. J. Cardiol., 2014, 172 (1), 263-5. doi:10.1016/j.ijcard.2013.12.262
31. Farkas, K.; Siraly, E.; Szily, E.; Csukly, G.; Rethelyi, J. Clinical characteristics of 5 hospitalized 3, 4-methylenedioxypyrovalerone (MDPV) users. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata 2013, 28 (4), 431-9. DOI: 10.12659/AJCR.889381
32. Sivagnanam, K.; Chaudari, D.; Lopez, P.; Sutherland, M. E.; Ramu, V. K. "Bath salts" induced severe reversible cardiomyopathy. Am. J. Case Rep., 2013, 14, 288-91. DOI:10.1159/000106681
33. Srikanth, S.; Barua, R.; Ambrose, J. Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology, 2008, 109 (3), 188-92. DOI:10.1159/ 000106681
34. Marinetti, L. J.; Antonides, H. M. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J. Anal. Toxicol., 2013, 37 (3), 135-46. doi: 10.1093/jat/bks136
35. Wright, T. H.; Cline-Parhamovich, K.; Lajoie, D.; Parsons, L.; Dunn, M.; Ferslew, K. E. Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J. Forensic Sci., 2013, 58 (6), 1558-62. DOI: 10.1111/1556- 4029.12260
36. Baumann, M.; Partilla, J.; Lehner, K. R., Thorndike, E. B.; Hoffman, A. F.; Holy, M.; Rothman, R. B.; Goldberg, S. R.; Lupica, C. R.; Sitte, H. H.; Brandt, S. D.; Tella, S. R.; Cozzi, N. V.; Schindler, C. W. Powerful Cocaine-Like Actions of 3, 4- Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive 'Bath Salts' Products. Neuropsychopharmacology, 2012, 38 (4), 552-62. doi: 10.1038/npp.2012.204.
37. Snyder, G. L.; Vanover, K. E. Intracellular Signaling and Approaches to the Treatment of Schizophrenia and Associated Cognitive Impairment. Curr. Pharm. Design, 2014, 20(31), 5093- 103. DOI: 10.2174/1381612819666131216115417
38. Fiorentini, A.; Volonteri, L. S.; Dragogna, F.; Rovera, C.; Maffini, M.; Mauri, M. C.; Altamura, C. A. Substance-induced psychoses: a critical review of the literature. Curr. Drug Abuse Rev., 2011, 4 (4), 228-40. DOI: 10.2174/1874473711104040228
39. Angoa-Perez, M.; Kane, M. J.; Briggs, D. I.; Francescutti, D. M.; Sykes, C. E.; Shah, M. M.; Thomas, D. M.; Kuhn, D. M. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J. Neurochem., 2013, 125 (1), 102-10. DOI: 10.1111/jnc.12114
40. Mash, D. C.; Pablo, J.; Ouyang, Q.; Hearn, W. L.; Izenwasser, S. Dopamine transport function is elevated in cocaine users. J. Neurochem., 2002, 81 (2), 292-300. DOI: 10.1046/j.1471-4159. 2002.00820.x
41. Mash, D. C.; Duque, L.; Pablo, J.; Qin, Y.; Adi, N.; Hearn, W. L.; Hyma, B. A.; Karch, S. B.; Druid, H.; Wetli, C. V. Brain biomarkers for identifying excited delirium as a cause of sudden death. Forensic Sci. Int., 2009, 190 (1-3), e13-9. doi:10.1016/j. forsciint.2009.05.012
42. Vincent, S. G.; Waddell, A. E.; Caron, M. G.; Walker, J. K.; Fisher, J. T. A murine model of hyperdopaminergic state displays altered respiratory control. FASEB, 2007, 21 (7), 1463-71. doi:10.1096/fj. 06-7248com
43. Huang, P. K.; Aarde, S. M.; Angrish, D.; Houseknecht, K. L.; Dickerson, T. J.; Taffe, M. A. Contrasting effects of dmethamphetamine, 3, 4-methylenedioxymethamphetamine, 3, 4- methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend., 2012, 126 (1-2), 168- 75. doi:10.1016/j.drugalcdep.2012.05.011